DME

OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone that has the potential to be the first topical eye drop and non-invasive treatment for DME.

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

New DME treatments aim to extend time between intravitreal injections.

A recent clinical trial from the DRCR Retina Network examined a stepped regimen of anti-VEGF drugs bevacizumab and aflibercept.

IBI324 is a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.

Proper screenings, treatment, management needed for this increasingly prevalent disease.

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

Advancements enable better diagnosis, treatment of patients.

A decade after the conclusion of the NIH-funded AREDS2 study, researchers found that the AREDS2 formula also reduces the risk of lung cancer.

All data were collected in the Fight Retinal Blindness! Registry.

This is the second FDA-approved indication for BEOVU; it was initially approved in 2019 for the treatment of wet AMD.

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

Oxurion NV finds insufficient evidence of efficacy on key clinical endpoints for THR-687 in Part A of the INTEGRAL phase 2 trial; focus will now turn to an alternative candidate and trial.

Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.

Researchers found that patients with nAMD lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.

Elevatum was created as a phase 4, multicenter, open-label, single-arm trial to specifically study Vabysmo (faricimab-svoa) in these underrepresented populations.

This latest approval for Beovu (brolucizumab) 6 mg is the second indication granted by the EC, as it was first approved in 2020 for the treatment of AMD.

Faricimab is now the first and only FDA-approved drug to target two distinct pathways known to cause retinal disease that may lead to vision loss.